• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

May 21, 2012

View Archived Issues

Pharma: Other News To Note

• Pfizer Inc., of New York, presented reports of studies on Lyrica (pregabalin) at the American Pain Society meeting in Honolulu, including an exploratory study, using functional magnetic resonance imaging (fMRI), showing that Lyrica decreased connectivity between various parts of the brain involved in pain processing in fibromyalgia patients. Read More

Clinic Roundup

• NovaBay Pharmaceuticals Inc., of Emeryville, Calif., said it enrolled the first patients in its Phase IIb study, named BAYnovation, to test lead compound NVC-422 in adenoviral conjunctivitis. Read More

Stock Movers

Read More

Other News To Note

• Emergent BioSolutions Inc., of Rockville, Md., said the FDA approved its supplemental biologics license application to change the administration schedule of BioThrax (anthrax vaccine adsorbed) to a three-dose primary series of intramuscular injections at zero, one month and six months. Read More

Financings Roundup

• Kleiner Perkins Caufield & Byers, of Menlo Park, closed KPCB 15, a $525 million venture capital fund focusing on investments in early stage digital consumer and enterprise, green tech and life sciences companies. Read More

Oncolix Seeks Funding for Prolactin Antagonist Trials

Five years after its founding and 15 years after work started on its lead compound, Oncolix Inc. is finally reaching out to venture capitalists for funding. The Houston-based start-up has thus far managed without big-money backers because the academics and contractors who've come into contact with its prolactin antagonist Prolanta (G129R) have been eager to lend their support. Read More

Scientists Show Why ApoE4 is Alzheimer's Disease Risk Factor

Having the ApoE4 gene variant is one of the strongest risk factors for developing late-onset Alzheimer's disease. Now, scientists have found out why. ApoE4 is less able to control production of the inflammatory cytokine cyclophilin A than other variants of the ApoE gene, and high levels of cyclophilin A set off inflammatory processes that ultimately damage the blood-brain barrier and the brain vasculature. Read More

Clouds Form on Horizon as PDUFA Heads to Senate

WASHINGTON – The first PDUFA clouds are forming as a revised version of the user fee package heads to the Senate floor this week for possible amendments and a vote. Read More

Canadian Stem Cell Approval Could Be the First of Many

Osiris Therapeutics Inc. won a double victory today with the first ever marketing approval for a manufactured stem cell product and the first therapy for graft-vs.-host disease (GvHD). Health Canada issued marketing authorization for Osiris's stem cell therapy Prochymal (remestemcel-L) for GvHD in children. Read More

Bench Press

Researchers from Weill Cornell Medical College reported this week that methylation of messenger RNA is widespread. It has only recently been recognized that messenger RNA, which was once thought to be a straightforward translational device between DNA and proteins, is methylated at all. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe